EGFR Mutation Positive Non-small Cell Lung Cancer
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(2)
Compare drugs
Frequently asked questions
How many drugs are in development for EGFR Mutation Positive Non-small Cell Lung Cancer?
BioSniper tracks 2 drugs in development for EGFR Mutation Positive Non-small Cell Lung Cancer across 1 company.
How many clinical trials target EGFR Mutation Positive Non-small Cell Lung Cancer?
There are 1 clinical trial targeting EGFR Mutation Positive Non-small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of EGFR Mutation Positive Non-small Cell Lung Cancer?
The estimated prevalence of EGFR Mutation Positive Non-small Cell Lung Cancer is approximately 75.0 per 100,000 population.
Deep-dive into EGFR Mutation Positive Non-small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis